Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.

Shin MC, Zhao J, Zhang J, Huang Y, He H, Wang M, Min KA, Yang VC.

J Biomed Mater Res A. 2015 Jan;103(1):409-419. doi: 10.1002/jbm.a.35188. Epub 2014 Apr 23.

2.

Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.

Shin MC, Zhang J, Ah Min K, Lee K, Moon C, Balthasar JP, Yang VC.

J Control Release. 2014 Nov 28;194:197-210. doi: 10.1016/j.jconrel.2014.08.030. Epub 2014 Sep 7.

3.

PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.

Shin MC, Zhang J, Min KA, He H, David AE, Huang Y, Yang VC.

Pharm Res. 2015 Aug;32(8):2690-703. doi: 10.1007/s11095-015-1653-y. Epub 2015 Feb 21.

4.

Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy.

Ham S, Min KA, Yang JW, Shin MC.

Arch Pharm Res. 2017 Sep 12. doi: 10.1007/s12272-017-0953-7. [Epub ahead of print]

PMID:
28900896
5.

Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.

Shin MC, Zhang J, David AE, Trommer WE, Kwon YM, Min KA, Kim JH, Yang VC.

J Control Release. 2013 Nov 28;172(1):169-78. doi: 10.1016/j.jconrel.2013.08.016. Epub 2013 Aug 23.

6.

Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity.

Shin MC, Min KA, Cheong H, Moon C, Huang Y, He H, Yang VC.

Pharm Res. 2016 Sep;33(9):2218-2228. doi: 10.1007/s11095-016-1959-4. Epub 2016 Jun 1.

7.

PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.

Kwon YM, Li YT, Liang JF, Park YJ, Chang LC, Yang VC.

J Control Release. 2008 Sep 24;130(3):252-8. doi: 10.1016/j.jconrel.2008.06.017. Epub 2008 Jun 26.

8.
11.

Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.

Han T, Tang Y, Ugai H, Perry LE, Siegal GP, Contreras JL, Wu H.

Virol J. 2007 Oct 24;4:103.

12.

HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct.

Meriläinen O, Hakkarainen T, Wahlfors T, Pellinen R, Wahlfors J.

Int J Oncol. 2005 Jul;27(1):203-8.

PMID:
15942661
13.

Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment.

Shin MC, Min KA, Cheong H, Moon C, Huang Y, He H, Yang VC.

Int J Pharm. 2017 May 30;524(1-2):101-110. doi: 10.1016/j.ijpharm.2017.03.072. Epub 2017 Mar 27.

PMID:
28359823
14.

Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels.

Bai Y, Gou M, Yi T, Yang L, Liu L, Lin X, Su D, Wei Y, Zhao X.

Int J Med Sci. 2015 May 8;12(5):397-406. doi: 10.7150/ijms.10929. eCollection 2015.

15.

Molecular tumor targeting of gelonin by fusion with F3 peptide.

Ham SH, Min KA, Shin MC.

Acta Pharmacol Sin. 2017 Jun;38(6):897-906. doi: 10.1038/aps.2017.20. Epub 2017 Apr 17.

PMID:
28414205
16.

Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells.

Park J, Ryu J, Kim KA, Lee HJ, Bahn JH, Han K, Choi EY, Lee KS, Kwon HY, Choi SY.

J Gen Virol. 2002 May;83(Pt 5):1173-81.

PMID:
11961273
17.

Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study.

Park YJ, Liang JF, Ko KS, Kim SW, Yang VC.

J Gene Med. 2003 Aug;5(8):700-11.

18.

Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD.

J Biol Chem. 2011 Feb 11;286(6):4165-72. doi: 10.1074/jbc.M110.186973. Epub 2010 Dec 7.

19.
20.

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.

Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG.

BMC Cancer. 2011 Aug 17;11:358. doi: 10.1186/1471-2407-11-358.

Supplemental Content

Support Center